NPNataliya Pasyechnikova

Nataliya Pasyechnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nataliya Pasyechnikova has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safeguarding patients’ vision over eight decades: 80 years of the Oftalmologicheskii Zhurnal

    by Nataliya Pasyechnikova, Svitlana Poliakova, Svitlana Slobodianyk, Olena Stoilovska, Hanna Arkusha

    In the history of Ukrainian medicine, there are journals that have become not just media to distribute publications, but true chronicles of particular fields of science. This is what the Ophthalmological Journal was and remains for Ukrainian ophthalmology. The journal was founded by Acad. V.P. Filatov as early as 1946, and has been shaping the face of Ukrainian ophthalmology for decades. Today we celebrate a significant milestone, the 80th anniversary of the journal.

  • Open Access

    A current view of the issue of rehabilitation of patients with ocular pathology

    by State Institution “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, S.V. Katsan, M.YU. Morozova, O.S. Zadorozhnyy, N.V. Pasyechnikova

    This paper considers general rehabilitation. In addition, attention is given to prospects for advancement in rehabilitation in the field of ophthalmology. The following major aspects of further development of the vision rehabilitation system in Ukraine were determined: 1) organization of up-to-date process of rehabilitation in the field of healthcare requires forming specialty rehabilitation units/words for persons with visual impairments (PVAs); 2) a comprehensive and continuous process of rehabilitation for PVAs should be achieved through established relationships among the parties involved; 3) rehabilitation is not only for people whose visual impairment is permanent and irremediable, but is primarily for those whose visual impairment is potentially remediable; 4) increasing awareness of vision rehabilitation issues among ophthalmologists and rehabilitation specialists should be a strategic objective of the healthcare system; 5) rehabilitation of vision should not only involve measures for adaptation of low-vision patients to new life conditions, but also should consider a range of measures aimed at optimizing visual function, including postoperative rehabilitation, post-medication rehabilitation, surgical rehabilitation, esthetic rehabilitation (including prosthetics), etc, and 6) developing specialty rehabilitation care for PVIs and moving forward from empirical approaches to an era of evidence-based practice requires further research on the efficacy of measures of medical vision rehabilitation. В роботі розглянуто загальні питання реабілітації, а також приділено увагу перспективам розвитку реабілітації в офтальмологічній галузі. Визначено першочергові аспекти подальшої розбудови системи реабілітації функції зору в Україні: 1) організація процесу реабілітації в сфері охорони здоров’я потребує створення спеціалізованих монопрофільних реабілітаційних відділень, підрозділів, які спеціалізуються на реабілітації осіб з погіршенням зору;2) комплексний підхід до процесу реабілітації осіб з погіршенням зору має бути досягнутий за рахунок налагоджених зв’язків між його учасниками; 3) реабілітації функції зору потребують не лише особи зі стійкою невиліковною втратою зорових функцій, а насамперед особи з погіршенням зору, у яких є потенціал відновлення зорових функцій; 4) підвищення обізнаності офтальмологів та фахівців з реабілітації у питаннях реабілітації зору є стратегічним завданням системи охорони здоров'я; 5) реабілітація зору повинна включати не лише заходи адаптації до нових умов життя слабкозорих чи втративших зір пацієнтів, а й розглядати коло заходів, спрямованих на максимальне відновлення функцій включно з післяопераційною реабілітацією, реабілітацією після медикаментозного лікування, хірургічною реабілітацією, естетичною реабілітацією (в т.ч. протезуванням) тощо; 6) розвиток вузькоспеціалізованої реабілітаційної допомоги та перехід від емпіричних підходів до епохи доказової практики потребує подальших наукових досліджень ефективності засобів медичної реабілітації зору.


  • Open Access

    Thermoelectric Measuring Equipment for Perioperative Monitoring of Temperature and Heat Flux Density of the Human Eye in Vitreoretinal Surgery

    by Roman Kobylianskyi, Krzysztof Przystupa, Valentyn Lysko, Jacek Majewski, Lyudmyla Vikhor, Vadym Boichuk, Oleg Zadorozhnyy, Orest Kochan, Mykola Umanets, Nataliya Pasyechnikova

    Perioperative monitoring of the ocular heat transfer is important for increasing the safety of long-term vitreoretinal surgery. The study is aimed at studying new thermoelectric measuring devices for comprehensive perioperative monitoring of ocular temperature and heat fluxes in vitreoretinal surgery. This pilot, open-label, prospective study included 23 patients (23 eyes) with proliferative diabetic retinopathy (PDR) in both eyes. The thermoelectric devices were developed for measuring intraocular temperature in vitreoretinal surgery and for determining the ocular surface temperature (OST) and heat flux (HF) density. In all cases, OST and HF density of both eyes were recorded (before and after surgery). Intraocular temperature and temperature of the irrigation fluid were measured intraoperatively. No complications associated with the perioperative use of thermoelectric temperature and HF sensors were identified during the study. The successful application of thermoelectric temperature and HF sensors, developed specifically for ophthalmological applications, in comprehensive perioperative monitoring of ocular heat transfer in patients with PDR in vitreoretinal surgery was demonstrated for the first time. Further research is needed to confirm the benefits of perioperative temperature monitoring in vitreoretinal surgery, as well as to develop equipment for active management of temperature in surgical practice.


  • Contemporary aspects of clinical manifestations and diagnosis of ocular tuberculosis: a literature review

    by Nataliya Pasyechnikova, Oleksandra Zborovska, Nataliia Konovalova, Oleksandra Dorokhova, Viktoriia Kolesnichenko

    Contemporary aspects of clinical manifestations and diagnosis of ocular tuberculosis: a literature review Nataliya V. Pasyechnikova, Oleksandra V. Zborovska, Nataliia V. Konovalova, Oleksandra E. Dorokhova, Viktoriia V. Kolesnichenko State Institution «V. P. Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine», Frantsuzkyi Boulevard, 49/51, Odesa 65015, Ukraine Tuberculosis remains one of the leading infectious diseases worldwide, and ocular tuberculosis (OTB) represents a particularly challenge due to the diversity of its clinical presentations. This review article systematizes and critically analyzes current evidence on clinical phenotypes and diagnostic methods for OTB. Particular attention is paid to the strengths and weaknesses of existing studies, their methodological limitations, and gaps in the evidence base. Literature analysis shows that OTB most often manifests as posterior uveitis but can mimic other inflammatory ocular diseases; retinal vasculitis remains one of the most challenging phenotypes to differentiate. Immunological tests (tuberculin skin test, IGRA) show limited accuracy, while promising biomarkers (BAFF, CXCL9) are still only experimental studies. Molecular methods (PCR, GeneXpert Ultra) provide rapid verification and determination of specific resistance, but their sensitivity in intraocular samples remains insufficient. Multimodal imaging is indispensable for identifying active lesions and monitoring disease course, although its results are not pathognomonic. Thus, this review demonstrates that no single method can be considered the “gold standard” in diagnosing ocular tuberculosis. Patient management requires a multimodal approach that integrates clinical, laboratory, and imaging data. Further prospective multicenter studies are needed to establish standardized diagnostic criteria. Keywords: ocular tuberculosis, diagnostics, clinic.

  • Open Access

    Ocular surface heat flux density as a biomarker related to diabetic retinopathy (pilot study)

    by Lukyan Anatychuk, Roman Kobylianskyi, Oleg Zadorozhnyy, Taras Kustryn, Illia Nasinnyk, Andrii Korol, Nataliya Pasyechnikova


  • Open Access

    Subthreshold Micropulse Laser (577 nm) Therapy with an Individual Approach for Power Titration in Patients with Chronic Central Serous Chorioretinopathy (Pilot Study)

    by Taras Kustryn, Oleg Zadorozhnyy, Illia Nasinnyk, Nataliya Pasyechnikova, Andrii Korol

    Purpose. To study the safety and effectiveness of subthreshold micropulse (SML) 577 nm laser therapy with an individual power titration in treating patients with chronic central serous chorioretinopathy (CSC). Methods. The study was a prospective, single‐centre observation of 30 patients (30 eyes) with chronic CSC. All patients with chronic CSC were treated with a 577 nm micropulse laser. Individual power parameters for each patient were titrated in a micropulse mode. The primary outcome measure was best‐corrected visual acuity (BCVA) at 6‐month follow‐up. The secondary outcome measures were as follows: central retinal thickness (CRT) and maximum subretinal fluid height (SRFH) according to optical coherence tomography, number of laser sessions, and treatment safety at 6‐month follow‐up. Results. Before treatment, the mean BCVA was 0.35 ± 0.16, the mean CRT was 285 ± 76 µm, and the mean SRFH was 311 ± 85 µm. Six months after 577 nm SML therapy, there was a statistically significant increase in the mean BCVA with the maximum correction to 0.45 ± 0.15 (p = 0.001). The mean CRT and SRFH decreased significantly to 236 ± 45 μm (p = 0.003) and 45 ± 25 μm (p = 0.001), respectively. At the end of the follow‐up, complete resorption of the subretinal fluid was noted in 50% (15 eyes), and in 43% (13 eyes), a decrease in the SRFH was observed. During the entire observation period, 25 patients underwent 1 session of 577 nm SML therapy, 2 patients underwent 2 sessions, and 3 patients underwent the intervention three times. Conclusion. SML 577 nm therapy with individual selection of laser power in a micropulse mode is a safe and effective method of treating patients with chronic CSC. Further studies are needed to test the long‐term safety and efficacy of 577 nm SML therapy with individual power settings in chronic CSC.


  • Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up

    by Andrii Korol, Taras Kustryn, Oleg Zadorozhnyy, Natalya Pasyechnikova, Igor Kozak

    Purpose: To compare the 24-month efficacy of intravitreal ranibizumab and aflibercept in treatment-naive patients with myopic choroidal neovascularization (CNV). Methods: Ninety-six naive patients (97 eyes) with myopic CNV were included in this single-center study. Patients received intravitreal ranibizumab (IVR) or aflibercept (IVA) following a pro re nata regimen (PRN). Results: Fifty patients (50 eyes) received 0.5 mg IVR, 46 patients (47 eyes) received 2.0 mg of IVA. There was no significant between-group difference in mean decimal best-corrected visual acuity (BCVA) (P = 0.6) or mean central retinal thickness (CRT) (P = 0.9) at 24 months. The mean ± standard deviation (SD) BCVA at baseline in the IVR group was 0.21 ± 0.14 and 0.20 ± 0.14 in the IVA group. At month 24, BCVA was 0.43 ± 0.24 (P < 0.001) in the IVR group and 0.41 ± 0.2 (P < 0.001) in the IVA group. Baseline mean ± SD CRT was 318 ± 84 microns in the IVR group and 303 ± 65 microns in the IVA group. At month 24, CRT was 226 ± 31 microns in the IVR group (P < 0.001) and 224 ± 35 microns in the IVA group (P < 0.001). There were no significant differences in the mean number of injections between the IVR group and the IVA group (2.9 ± 1.2 vs. 2.8 ± 1.1), (P = 0.7). Conclusions: Our study demonstrates that ranibizumab and aflibercept in a PRN regimen lead to a significant increase of BCVA and decrease in central foveal thickness in treatment-naive patients with myopic CNV after 24 months.


  • Open Access

    Biomaterials-enabled cornea regeneration in patients at high risk for rejection of donor tissue transplantation

    by M. Mirazul Islam, Oleksiy Buznyk, Jagadesh C. Reddy, Nataliya Pasyechnikova, Emilio I. Alarcon, Sally Hayes, Philip Lewis, Per Fagerholm, Chaoliang He, Stanislav Iakymenko, et al.

    The severe worldwide shortage of donor organs, and severe pathologies placing patients at high risk for rejecting conventional cornea transplantation, have left many corneal blind patients untreated. Following successful pre-clinical evaluation in mini-pigs, we tested a biomaterials-enabled pro-regeneration strategy to restore corneal integrity in an open-label observational study of six patients. Cell-free corneal implants comprising recombinant human collagen and phosphorylcholine were grafted by anterior lamellar keratoplasty into corneas of unilaterally blind patients diagnosed at high-risk for rejecting donor allografts. They were followed-up for a mean of 24 months. Patients with acute disease (ulceration) were relieved of pain and discomfort within 1–2 weeks post-operation. Patients with scarred or ulcerated corneas from severe infection showed better vision improvement, followed by corneas with burns. Corneas with immune or degenerative conditions transplanted for symptom relief only showed no vision improvement overall. However, grafting promoted nerve regeneration as observed by improved touch sensitivity to near normal levels in all patients tested, even for those with little/no sensitivity before treatment. Overall, three out of six patients showed significant vision improvement. Others were sufficiently stabilized to allow follow-on surgery to restore vision. Grafting outcomes in mini-pig corneas were superior to those in human subjects, emphasizing that animal models are only predictive for patients with non-severely pathological corneas; however, for establishing parameters such as stable corneal tissue and nerve regeneration, our pig model is satisfactory. While further testing is merited, we have nevertheless shown that cell-free implants are potentially safe, efficacious options for treating high-risk patients.


  • Notfallkeratoplastik mit porcinen Xenotransplantaten bei nekrotisierender Keratitis

    by Galyna I. Drozhzhyna, Tetiana B. Gaidamaka, Claus Cursiefen, Björn O. Bachmann, Olena V. Ivanovska, Viktor L. Ostashevsky, Boris M. Kogan, Volodymyr J. Usov, Natalija V. Pasyechnikova

    Hintergrund Der große Mangel an Spendermaterial in der Ukraine macht es notwendig, zusätzliche Quellen von Transplantationsmaterial zu finden. Ein möglicherweise geeignetes Material ist die Hornhaut von Schweinen, weil sie in ihrer Struktur und ihren biomechanischen Parametern der menschlichen Hornhaut ähnlich ist. Das Ziel unserer Studie war, die Ergebnisse der therapeutischen Keratoplastik (KP) mit Keratoxenotransplantaten aus gefriergetrockneten porcinen Xenotransplantaten bei Patienten mit schwerer nekrotisierender Keratitis zu analysieren. Material und Methoden Retrospektive Analyse von 32 Xenotransplantationen (32 Patienten) mit schwerer nekrotisierender Keratitis (17 lamelläre, 6 gestufte perforierende, 4 perforierende, 5 „biologische Deckungen“ nach Puchkovskaya). Ergebnisse Alle Augen konnten erhalten werden, das Transplantat wurde jedoch in allen Augen abgestoßen. Ein semitransparentes Xenotransplantat (XT) wurde bei 9 Patienten (33,3%) erreicht. Die besten Ergebnisse wurden nach lamellärer XKP (Xenokeratoplastik) mit einem (XT) Durchmesser von 3,5 – 6,5 mm erreicht. Lamelläre XT mit größerem Durchmesser (7,0 – 10,0 mm) waren trüb. Postoperativ war die Intensität der entzündlichen Reaktion nach gestufter XKP etwas niedriger als nach der klassischen perforierenden XKP. Im Verlauf musste bei 5 Patienten eine erneute KP mit humaner Hornhaut durchgeführt werden, in einem Fall gleichzeitig mit einer antiglaukomatösen Operation und in einem anderen Fall mit Kataraktextraktion. Antiglaukomatöse Operationen mussten bei 5 Patienten durchgeführt werden (15,6%). Schlussfolgerung Bei Abwesenheit von humanen Spenderhornhäuten kann im Notfall ein porcines Keratoxenoimplantat als temporäre therapeutische Keratoplastik verwendet werden, um den Entzündungsprozess zu stoppen und das Auge zu retten. Background The great shortage of donor material in Ukraine makes it necessary to find additional sources of transplant material. A possible suitable material are the porcine corneas, as they are similar in structure and biomechanical parameters to the human cornea. The purpose of our study was to analyze the results of therapeutic keratoplasty (KP) with keratoxenotransplants from cryolyophilized porcine corneas in patients with severe necrotizing keratitis. Methods A retrospective analysis of 32 xenotransplantations patients with severe necrotizing keratitis (17 lamellar, 6 stepped perforating, 4 perforating, 5 “biological coverage” according to Puchkovskaya) was completed. Results All eyes could be preserved, but the graft was rejected in all eyes. A semitransparent xenograft (XG) was achieved in 9 patients (33.3%). The best results were obtained after lamellar XKP with an XT diameter of 3.5 – 6.5 mm. Lamellar XTs with larger diameters (7.0 – 10.0 mm) were opaque. Postoperatively, the intensity of the inflammatory response after stepped XKP was slightly lower than that of the classical perforating XKP. A new KP with human corneas had to be performed in 5 patients, in one case combined with an antiglaucomatous operation and in another case with cataract extraction. Antiglaucomatous surgery had to be performed in 5 patients (15.6%). Conclusion In the absence of human donor corneas, a porcine keratoxenoimplant can be used as temporary therapeutic keratoplasty in case of emergency stop the inflammation process and to save the eye. In cases of keratoxenoimplant, a poor visual outcome is expected.